In our study, we develop and validate a prognostic signature (named TILTregSig) composed of five Treg-specific mRNAs (SOCS2, EGR1, RRM2, TPP1, and C11orf54) for prostate cancer, which is associated with RFS in prostate cancer. Here, SOCS2 is linked to prostate cancer.